Business Wire

BSMO

1.2.2021 01:32:14 CET | Business Wire | Press release

Share
Notice Regarding Business Alliance With BSMO Co., Ltd. and SBI Africa Co., Ltd.

BSMO Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director: Tadashi Shimizu, hereinafter "BSMO") has announced today that BSMO has entered into a business alliance agreement with SBI Africa Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director: Tomoya Kitagawa, hereinafter "SBI Africa").

1. Background

As a pioneer in the field of SNS marketing, BSMO, through the best use of D2C x SNS marketing expertise and technology, provides one-stop growth hacking services for D2C e-commerce companies and helps deliver high-quality Japanese products and services to the world.

The population of Africa, where many emerging countries are located, is expected to double from 1.06 billion in 2019 to 2.11 billion people in 2050, according to the latest United Nations projections.

With the rapid population growth and economic growth in the African countries, the automobile usage rate is increasing every year which is driving a strong demand for reliable and affordable used cars from Japan.

By forming a business alliance with SBI Africa, which exports Japanese used cars to emerging countries, BSMO will introduce its D2C x SNS marketing expertise and technology to the SBI Group in order to strengthen the D2C exports in Africa, and thus improve the profitability and corporate values of both parties.

2. Details of the Business Alliance

(1) Improving the quality of SBI Africa's products and services by providing marketing research, advertising strategies, measurement strategies, design strategies, AI analytics, operations services and customer support services.
(2) Improving the profitability and brand value of both parties in the African region through joint sales of BSMO affiliated products and services on SBI Africa’s cross-border e-commerce website.
(3) Jointly providing system development and marketing strategy services for Japanese companies operating in Africa.
(4) Improving the profitability of BSMO and the marketing capabilities of SBI Group, through BSMO’s introduction of its marketing expertise and technology to SBI Group, etc.

[Company Overview]

Name

BSMO Co., Ltd.

Location

1-17-1 Toranomon, Minato-ku, Tokyo Toranomon Hills Business Tower 14th floor

Representative

Tadashi Shimizu

Business Description

D2C marketing business, global growth hack business using SNS, branding business, media business, system development business, artificial intelligence (AI) development business, etc.

Name

SBI Africa Co., Ltd.

Location

1-6-1 Roppongi, Minato-ku, Tokyo Izumi Garden Tower 15F

Representative

Tomoya Kitagawa

Business Description

Overseas export business of domestic used cars, financial service provision business in partnership with overseas financial institutions, venture capital investment targeting the African region, etc.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye